Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is up over 16% today on news of the company’s initiation of phase-II trials for its lead drug candidate KRN23, which is a monoclonal antibody for X-linked Hypophosphatemia (XLH). Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock performance was 14.30% in last session and finished the day at $48.67. Traded volume was 435,645.00million shares in the last session and the average volume of the … Continue reading Healthcare Stocks In News: Ultragenyx (NASDAQ:RARE), Flexion (NASDAQ:FLXN), Receptos Inc (NASDAQ:RCPT), Acorda Therapeutics (NASDAQ:ACOR), Aratana Therapeutics (NASDAQ:PETX)